Thermo Fisher Scientific (TMO) EBIT (2009 - 2026)

Thermo Fisher Scientific has disclosed EBIT across 18 years of filings, most recently posting $1.9 billion for Q1 2026.

• Quarterly EBIT rose 8.57% year-over-year to $1.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 billion (up 6.81% YoY) and the FY2025 annual result came in at $7.7 billion, up 5.57% from the prior year.
• EBIT fell to $1.9 billion in Q1 2026, from $2.3 billion in the prior quarter.
• Over five years, EBIT peaked at $2.8 billion in Q2 2022 and troughed at $1.6 billion in Q2 2023.
• A 5-year average of $1.9 billion and a median of $1.9 billion in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2023 — EBIT sank 44.59% — and 2024, when it climbed 15.34%.
• Tracing TMO's EBIT over 5 years: stood at $1.9 billion in 2022, then decreased by 0.38% to $1.9 billion in 2023, then rose by 8.74% to $2.0 billion in 2024, then rose by 11.86% to $2.3 billion in 2025, then decreased by 17.38% to $1.9 billion in 2026.
• Business Quant data shows TMO's EBIT at $1.9 billion in Q1 2026, $2.3 billion in Q4 2025, and $1.9 billion in Q3 2025.